Literature DB >> 3540007

An isoelectric focusing overlay study of the humoral immune response in Theiler's virus demyelinating disease.

R P Roos, E A Nalefski, S Nitayaphan, R Variakojis, K K Singh.   

Abstract

Oligoclonal immunoglobulin G (IgG) bands are a frequent feature of inflammatory diseases of the central nervous system (CNS). In multiple sclerosis (MS), cerebrospinal fluid (CSF) oligoclonal IgG bands are a potential clue to the pathogenesis of the disease; however, their particular antigenic target is unknown. We sought to characterize the IgG response in an experimental CNS persistent demyelinating infection by isoelectric focusing (IEF) studies of serum and CSF from mice infected with Theiler's murine encephalomyelitis virus (TMEV). Following IEF, we used a new technique in order to identify TMEV-specific antibodies; focused immunoglobulins were blotted onto nitrocellulose paper which was then overlaid with radiolabeled virus. Autoradiograms showed that most of the TMEV antibody was locally synthesized within the CNS since CSF, but not serum, TMEV antibody had an anodal distribution. CSF IEF TMEV antibody spectrotypes were very similar, presumably because the CSFs were collected from the same inbred mouse strain. CSF TMEV antibody displayed less restricted heterogeneity than the very restricted cathodal CSF oligoclonal IgG bands seen in MS. The new IEF immunoblotting antigen overlay technique will be a powerful detection system to probe for the antigenic target against which MS CSF IgG may be directed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3540007     DOI: 10.1016/0165-5728(87)90066-x

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  11 in total

1.  Incidence of Helicobacter pylori infection in a cohort of Italian military students.

Authors:  R Biselli; M Fortini; P M Matricardi; T Stroffolini; R D'Amelio
Journal:  Infection       Date:  1999 May-Jun       Impact factor: 3.553

Review 2.  Viruses and multiple sclerosis.

Authors:  Gregory P Owens; Don Gilden; Mark P Burgoon; Xiaoli Yu; Jeffrey L Bennett
Journal:  Neuroscientist       Date:  2011-12       Impact factor: 7.519

3.  Signature biochemical properties of broadly cross-reactive HIV-1 neutralizing antibodies in human plasma.

Authors:  Mohammad M Sajadi; George K Lewis; Michael S Seaman; Yongjun Guan; Robert R Redfield; Anthony L DeVico
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

4.  Anti-V3 loop spectrotype in HIV-infected individuals during zidovudine therapy.

Authors:  R Biselli; V Del Bono; M Anselmo; A Canessa; G Mazzarello; R D'Amelio; D Bassetti
Journal:  Infection       Date:  1996 May-Jun       Impact factor: 3.553

Review 5.  Theiler's virus infection: a model for multiple sclerosis.

Authors:  Emilia L Oleszak; J Robert Chang; Herman Friedman; Christos D Katsetos; Chris D Platsoucas
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

6.  Spectrotypic analysis of antibodies to Helicobacter pylori in patients with antral gastritis and duodenal ulcer.

Authors:  R Biselli; D Vaira; R Nisini; M Miglioli; L Menegatti; L Barbara; R D'Amelio
Journal:  J Clin Pathol       Date:  1995-12       Impact factor: 3.411

7.  Analysis of antibody responses to predominant linear epitopes of Theiler's murine encephalomyelitis virus.

Authors:  A Inoue; Y K Choe; B S Kim
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

8.  Study of the mechanisms by which CD4+ T cells contribute to protection in Theiler's murine encephalomyelitis.

Authors:  P Borrow; C J Welsh; A A Nash
Journal:  Immunology       Date:  1993-11       Impact factor: 7.397

Review 9.  Immunology of Theiler's murine encephalomyelitis virus infection.

Authors:  E L Oleszak; J Kuzmak; R A Good; C D Platsoucas
Journal:  Immunol Res       Date:  1995       Impact factor: 2.829

Review 10.  Excessive Innate Immunity Steers Pathogenic Adaptive Immunity in the Development of Theiler's Virus-Induced Demyelinating Disease.

Authors:  Byung S Kim
Journal:  Int J Mol Sci       Date:  2021-05-17       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.